Weekly Recap | Roivant Sciences +16.86%, closing in on record highs
I'm LongbridgeAI, I can summarize articles.Roivant Sciences (ROIV) gained 16.86% this week to close at $40.82, against a 0.8% decline for the S&P 500 — a 17.66 percentage point gap. The four-session week started with a sharp gap up on Tuesday (8 Sep), when the stock hit a high of $42.50 before settling at $41.48. It then eased to $41.81 and $40.94 over the next two days, ending Friday at $40.82. Trading was heavy, with average daily volume of about 12.1m shares, roughly 104% above the 60-day median.
The Week
Roivant Sciences (ROIV) gained 16.86% this week to close at $40.82, against a 0.8% decline for the S&P 500 — a 17.66 percentage point gap. The four-session week started with a sharp gap up on Tuesday (8 Sep), when the stock hit a high of $42.50 before settling at $41.48. It then eased to $41.81 and $40.94 over the next two days, ending Friday at $40.82. Trading was heavy, with average daily volume of about 12.1m shares, roughly 104% above the 60-day median.
Key Events
The main story was the positive PHocus readout for Mosliciguat in PH-ILD, alongside the unveiling of the ongoing Phase 3 PHrontier study. The news triggered a pre-market scramble on Tuesday, with intraday gains topping 20% and the stock reaching record highs. Jefferies, HC Wainwright and TD Cowen followed with rating updates, shifting the debate from a single data point to Phase 3 validation and the commercial ramp of LISRAYA. Elsewhere in the week, director Meghan FitzGerald disposed of roughly $798,000 in shares, while Virginia Retirement Systems and others bought 61,200 shares.
Analyst Ratings
Twelve brokers cover ROIV: 9 rate it buy, 2 overweight and 1 hold, with no underweight or sell ratings. The consensus is strong buy, with a target of $45.95, about 12.58% above the current $40.82. Targets range from $37.50 to $55.00, with the spread concentrated at the upper end. The stock ranks 94 out of 506 in its biotech sector, in the upper-middle tier.
The Week Ahead
The macro calendar is heavy next week: the New York Fed manufacturing index lands on Tuesday (15 Sep), followed on Wednesday (16 Sep) by retail sales, retail sales ex-autos, retail control, import prices and the NAHB housing index, plus weekly EIA crude inventories. For ROIV, the key follow-through is the pace of the Phase 3 PHrontier study after the PHocus data, and whether LISRAYA’s commercial launch can support the rerating.
In Short
ROIV’s move this week arrived alongside the Mosliciguat PHocus data, with positive broker coverage and a consensus target about 12.6% above spot — that is the pricing anchor for now. Against it, the latest session’s large-lot flow leaned net seller, and valuation remains rich on book value at about 6.97x, with negative trailing P/E, typical of an early-stage pipeline story. The question is whether Phase 3 data and commercial traction keep that narrative intact.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.